AUD2.34
0.86% today
Australia, Sep 16, 08:10 am CET
ISIN
AU000000MSB8
Symbol
MSB

Mesoblast Stock price

AUD2.34
-0.13 5.26% 1M
+0.26 12.50% 6M
-0.76 24.52% YTD
+1.42 154.35% 1Y
+1.46 165.37% 3Y
-2.30 49.53% 5Y
-0.70 23.06% 10Y
+1.87 398.62% 20Y
Australia, Closing price Tue, Sep 16 2025
+0.02 0.86%
ISIN
AU000000MSB8
Symbol
MSB
Industry

Key metrics

Basic
Market capitalization
AUD2.8b
Enterprise Value
AUD2.8b
Net debt
positive
Cash
AUD241.7m
Shares outstanding
1.3b
Valuation (TTM | estimate)
P/E
negative | negative
P/S
109.6 | 28.2
EV/Sales
107.7 | 27.7
EV/FCF
negative
P/B
3.2
Financial Health
Equity Ratio
76.1%
Return on Equity
-17.1%
ROCE
-12.1%
ROIC
-14.1%
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
AUD25.8m | AUD100.2m
EBITDA
- | AUD-63.1m
EBIT
AUD-123.4m | AUD-76.1m
Net Income
AUD-153.2m | AUD-356.3m
Free Cash Flow
AUD-75.9m
Growth (TTM | estimate)
Revenue
191.4% | 288.5%
EBITDA
- | 48.9%
EBIT
-23.0% | 38.4%
Net Income
-16.1% | -132.6%
Free Cash Flow
-3.9%
Margin (TTM | estimate)
Gross
70.2%
EBITDA
- | -63.0%
EBIT
-478.5%
Net
-593.9% | -355.6%
Free Cash Flow
-294.4%
More
EPS
AUD-0.1
FCF per Share
AUD-0.1
Short interest
-
Employees
73
Rev per Employee
AUD350.0k
Show more

Is Mesoblast a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,016 stocks worldwide.

Mesoblast Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Mesoblast forecast:

8x Buy
80%
2x Hold
20%

Analyst Opinions

10 Analysts have issued a Mesoblast forecast:

Buy
80%
Hold
20%

Financial data from Mesoblast

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
26 26
191% 191%
100%
- Direct Costs 7.69 7.69
67% 67%
30%
18 18
223% 223%
70%
- Selling and Administrative Expenses 59 59
66% 66%
229%
- Research and Development Expense 52 52
37% 37%
202%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -123 -123
23% 23%
-479%
Net Profit -153 -153
16% 16%
-594%

In millions AUD.

Don't miss a Thing! We will send you all news about Mesoblast directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Silviu Itescu on June 8, 2004 and is headquartered in Melbourne, Australia.

Head office Australia
CEO Silviu Itescu
Employees 73
Founded 2004
Website www.mesoblast.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today